Evidence map›Paper›PMID 37880793›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Exosomal long noncoding RNA MLETA1 promotes tumor progression and metastasis by regulating the miR-186-5p/EGFR and miR-497-5p/IGF1R axes in non-small cell lung cancer.

Xiu-Rui Hsu, Jia-En Wu, Yi-Ying Wu, Sheng-Yen Hsiao, Jui-Lin Liang, Ya-Ju Wu, Chia-Hao Tung, Meng-Fan Huang, Ming-Shiu Lin, Pan-Chyr Yang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Insulin-like growth factor receptor signaling in physiology and disease.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Xiu-Rui HsuInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Jia-En WuInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yi-Ying WuClinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Sheng-Yen HsiaoInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Jui-Lin LiangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ya-Ju WuDepartment of Pathology, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
Chia-Hao TungInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Meng-Fan HuangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ming-Shiu LinInstitute of Biomedical Sciences, Academia Sinica, Taipei, 115, Taiwan.
Pan-Chyr YangInstitute of Biomedical Sciences, Academia Sinica, Taipei, 115, Taiwan.
Yuh-Ling ChenInstitute of Oral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. yuhling@ncku.edu.tw.ORCID http://orcid.org/0000-0001-7760-5954
Tse-Ming HongInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. tmhong@ncku.edu.tw.
National Cheng Kung University · TWChi Mei Medical Center · TWInstitute of Biomedical Sciences, Academia Sinica · TWNational Cheng Kung University Hospital · TWNational Taiwan University · TW

Funding

Ministry of Science and Technology, Taiwan 110-2311-B-006-004-MY3Ministry of Science and Technology, Taiwan MOST 110-2314-B-006-097-MY3
6 · The paper itself

Abstract

backgroundLung cancer is the most common and deadliest cancer worldwide, and approximately 90% of all lung cancer deaths are caused by tumor metastasis. Tumor-derived exosomes could potentially promote tumor metastasis through the delivery of metastasis-related molecules. However, the function and underlying mechanism of exosomal long noncoding RNA (lncRNA) in lung cancer metastasis remain largely unclear.

methodsCell exosomes were purified from conditioned media by differential ultracentrifugation and observed using transmission electron microscopy, and the size distributions were determined by nanoparticle tracking analysis. Exosomal lncRNA sequencing (lncRNA-seq) was used to identify long noncoding RNAs. Cell migration and invasion were determined by wound-healing assays, two-chamber transwell invasion assays and cell mobility tracking. Mice orthotopically and subcutaneously xenografted with human cancer cells were used to evaluate tumor metastasis in vivo. Western blot, qRT‒PCR, RNA-seq, and dual-luciferase reporter assays were performed to investigate the potential mechanism. The level of exosomal lncRNA in plasma was examined by qRT‒PCR. MS2-tagged RNA affinity purification (MS2-TRAP) assays were performed to verify lncRNA-bound miRNAs.

resultsExosomes derived from highly metastatic lung cancer cells promoted the migration and invasion of lung cancer cells with low metastatic potential. Using lncRNA-seq, we found that a novel lncRNA, lnc-MLETA1, was upregulated in highly metastatic cells and their secreted exosomes. Overexpression of lnc-MLETA1 augmented cell migration and invasion of lung cancer. Conversely, knockdown of lnc-MLETA1 attenuated the motility and metastasis of lung cancer cells. Interestingly, exosome-transmitted lnc-MLETA1 promoted cell motility and metastasis of lung cancer. Reciprocally, targeting lnc-MLETA1 with an LNA suppressed exosome-induced lung cancer cell motility. Mechanistically, lnc-MLETA1 regulated the expression of EGFR and IGF1R by sponging miR-186-5p and miR-497-5p to facilitate cell motility. The clinical datasets revealed that lnc-MLETA1 is upregulated in tumor tissues and predicts survival in lung cancer patients. Importantly, the levels of exosomal lnc-MLETA1 in plasma were positively correlated with metastasis in lung cancer patients.

conclusionsThis study identifies lnc-MLETA1 as a critical exosomal lncRNA that mediates crosstalk in lung cancer cells to promote cancer metastasis and may serve as a prognostic biomarker and potential therapeutic target for lung cancer diagnosis and treatment.

Indexed as

Carcinoma, Non-Small-Cell LungExosomesLung NeoplasmsMicroRNAsRNA, Long NoncodingAnimalsCell Line, TumorCell MovementCell ProliferationErbB ReceptorsGene Expression Regulation, NeoplasticHumansMiceReceptor, IGF Type 1EGFR protein, humanErbB ReceptorsIGF1R protein, humanMicroRNAsMIRN186 microRNA, humanMIRN497 microRNA, humanReceptor, IGF Type 1RNA, Long NoncodingEGFRExosomeIGF1RLnc-MLETA1Lung cancer metastasismiR-186-5pmiR-497-5p

Identifiers

PMID37880793
PMCPMC10601119
OpenAlexW4387948820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.